Signet

News & Events - Advertising Press Release

Paul Haje’s ArrayIt® team wins ad award.

Sunnyvale, CA, August 7, 2003 – On August 4th Signet Research and PharmaGenomics announced that a recent ArrayIt® advertisement received the highest score of any Life Sciences company, winning by substantial numbers over competing ads by Applied Biosystems, Roche Diagnostics, Invitrogen, Amersham, and BD Biosciences. Mr. Haje’s advertisement appeared in the February 2003 issue of the journal PharmaGenomics, and featured ArrayIt®’s Super Microarray Substrates product line.

Signet Research Inc. was established in 1968 as a full-service marketing research firm specializing in gathering marketing and market information to fit specific client needs. Signet uses a combination of mail and electronic mail surveys, telephone and personal interviews, questionnaires, and focus groups to generate independently derived, object data. PharmaGenomics is an international scientific journal dedicated to serving the genomics, proteomics, drug discovery, and diagnostics communities. Signet performed an independent performance survey of all of the ads in PharmaGenomics, and assigned an AdProbe™ score of 88% to ArrayIt® compared to lesser scores for Bio-Rad Laboratories (69%), Applied Biosystems (68%), Roche (67%), Invitrogen (66%), Agilent Technologies (66%), Amersham (62%), and BD Biosciences (60%).

Paul Haje, ArrayIt®’s Director of Public Relations and Promotions, was delighted to learn of the Signet award. “My team and I devote a lot of creativity to our print ads, we work closely with the scientific and corporate staff at TeleChem to make sure our ads are technically sound, educational, and appealing. We were satisfied with the ad when it was completed, but had no idea it would achieve the top spot out of all the full-page ads evaluated in the Signet survey. To outperform seven of the world’s most distinguished public companies, having a combined market cap of over $50 billion and a combined advertising budget of over $3 billion - plus the other 21 companies we outperformed - is fantastic.”

About TeleChem International, Inc.
TeleChem is a privately held, profitable business with its activities organized into three corporate divisions: Life Sciences, Chemicals, and Diagnostics. The Life Sciences ArrayIt® Division provides a complete line of products and services for the microarray industry, a high-tech sector that uses tiny glass “chips” to explore the human genome. Microarray technology is speeding disease analysis, drug discovery, and crop plant development. The microarray products are sold under the ArrayIt® brand name, and include key patents (e.g. US 6,101,946) that protect the company’s core microarray manufacturing technology used in more than 10,000 corporate and university laboratories worldwide. The Chemicals Division provides import and export services and government contract work in the area of industrial chemicals including raw materials for plastics, water-soluble fertilizers, and cleaning compounds. The Chemicals Division enjoys expanding sales and profits, and provides financial support for research and development. The Diagnostics Division NGS-ArrayIt, Inc. has key patent filings in the areas of genotyping and medical diagnostics, and provides its tools and technologies to public health laboratories and other agencies involved in human disease analysis. NGS-ArrayIt plans to launch a new line of disease tests for sickle cell anemia, cystic fibrosis, hereditary hearing loss and other treatable diseases in the near future.

Media Contact
Paul Haje
Director of Public Relations
408-744-1331
Email paul@ArrayIt.com